

EDL Begins Patient Testing

EpineX is happy to report that EDL has begun testing patient samples and is well on its way to revenue generation. In order to accommodate the needs of our current and future clients, EpineX has installed and validated upgraded clinical lab equipment that is capable of accommodating higher volumes of tests. Newly acquired personnel include a laboratory technician, a clinical laboratory scientist, and several phlebotomists to provide on-site specimen collection and courier services. A follow-up inspection with the California State Laboratory Field Services has been scheduled for early next year.

EDL is currently working to secure reimbursement from both government and private payers. It has acquired a National Provider Identifier (NPI) number, has enrolled with Medicare, and is currently undergoing the credentialing and enrollment process with private insurance companies. EpineX is undergoing the credentialing process with Blue Shield, United Healthcare, Corvel, Interplan, Integrated, and the US Department of Labor. EDL will next attempt to enroll with additional carriers such as Health Net and Memorial Healthcare.

Hong Kong Patent Registered

EpineX has proceeded with registering the patent for the G1A™ test in Hong Kong pursuant to the granting of the European patent. EpineX expects the Hong Kong patent to be granted, translated, and published within the next year.

Scientific Advisory Board Update

EpineX Welcomes Dr. Alan Carter

EpineX is happy to welcome Dr. Alan Carter to the Scientific Advisory Board (SAB). Dr. Carter has over 20 years of experience in community pharmacy practice, hospital pharmacy practice, and clinical trial management. He has performed extensive research in diabetes monitoring and has been referred to as the "world's leading diabetes technology pharmacist" by the editor-in-chief of the Journal of Diabetes Science & Technology. He has been responsible for multisite management of multiple clinical trials that evaluated the design and application of metabolic biomarkers and medical devices at the point of care. Dr. Carter has consulted for companies such as Johnson & Johnson, LXN, Lockheed Martin, and the US Army Research Institute of Environmental Medicine. EpineX looks forward to the experience and knowledge that Dr. Alan Carter will bring to the team.



Alan W. Carter, PharmD
Chair, Kansas Diabetes
Action Council

Dr. Bennett to Assist EpineX Diagnostics Laboratories




EpineX CEO Asad Zaidi and SAB member Dr. Bennett present a poster on GA at the AACC Conference in 2007

Dr. Bennett, a devoted member of the SAB, resigned from the Board in September. He has directly assisted EpineX for over six years by helping to educate the scientific community on the benefits of glycated albumin through numerous presentations at scientific conferences worldwide. EpineX will continue to maintain its relationship with Dr. Bennett, particularly in developing its clinical laboratory business. EpineX looks forward to his invaluable expertise in the promotion of EDL services to the clinical testing community and is appreciative for the generous amount of time and resources he has put into the Company.

EpineX Launches New PPM

On November 7, 2011, EpineX launched a new private placement memorandum for \$5 million. As previously anticipated, the offering consists of up to 2.5 million units (each unit consisting of one share of common stock and a warrant to purchase an additional share of common stock) at \$2 per unit. The minimum subscription is \$25,000 for 12,500 units. All common shares will be registered with the SEC upon full subscription of the offering.



EpineX Chosen to Present at Exclusive Venture Meetings



EpineX CEO Asad Zaidi gives a presentation of the Company to a group of venture capitalists and angel investors

In November, EpineX was invited to present the Company at the CONNECT Venture Roundtable, an exclusive, invitation-only showcase for promising emerging companies in the Southern California region where premier venture capital providers and angel investors actively fund investments.

EpineX was one of six companies in Southern California that were selected out of the hundreds screened by a panel of distinguished judges. The presentation was well received by the audience, leading to an invitation to CONNECT's Venture Roundtable Roadshow in Palo Alto, CA.

GA Showcased at Kentucky's Annual Statewide Diabetes Symposium



The Kentucky Diabetes Prevention and Control Program (KDPCP) invited EpineX to participate in Kentucky's Annual Statewide Diabetes Symposium, held on November 18, 2011. Dr. Omar Ali, member of EpineX's scientific advisory board, gave a presentation titled "Glycated Albumin: A New Biomarker on the Horizon." The organizers received great feedback on the lecture. According to the Chair of the event, Dr. Ali "provided cutting-edge information that is extremely beneficial to the more than 260 educators in attendance." The talk provided a forum for healthcare professionals to be educated on the benefits of glycated albumin monitoring for diabetes management.


The meeting was organized by KDPCP, a public health initiative consisting of a network of state, regional, and local health professionals whose mission is to reduce new cases of diabetes as well as the sickness, disability, and death associated with diabetes and its complications. The meeting, attended by nurses, educators, physicians, and other healthcare professionals directly involved with diabetes management, was approved for continuing education credits.



EpineX scientific advisory board member Dr. Omar Ali speaks about the benefits of GA testing at the KDPCP symposium

Development Update

EpineX has recently expanded the R&D team to include Dr. Wing Liu as its senior research scientist. His expertise includes protein purification, conjugation chemistry, and assay development for the detection of biomarkers of clinical significance. Dr. Liu has published over 15 scientific papers in peer-reviewed journals and has worked as a research scientist at the Oklahoma Medical Research Foundation, the University of Toronto, Scantibodies Laboratory, Becton Dickinson Biosciences, Quidel, Abbott, and Biosite.



Wing Liu, PhD
Senior Research Scientist

With Dr. Liu's expertise and guidance, the R&D team is developing EpineX's own antibodies for the microalbuminuria test and is well on its way to developing this assay. Dr. Liu's experience will also be invaluable in the continued progress of the G1A™ assay.

At present, the R&D team is focusing on further characterization of the antibody-antigen interactions for the G1A™ strip in order to refine the test's reactivity and sensitivity. Testing with patient samples are currently in process.

EpineX Appoints Head of Manufacturing



Greg Hamilton
Director of Manufacturing

EpineX is in the process of preparing its manufacturing facility for several assays in EpineX's product portfolio. To this end, EpineX has recruited Mr. Gregory Hamilton as the Company's manufacturing director to establish the Company's manufacturing department and prepare the facility for upcoming inspections by the California Department of Public Health and the FDA. Mr. Hamilton has over 20 years' experience in the medical device lateral flow and molecular diagnostic reagents industries. He has managed and supervised chemistry and filling departments, automation, new product transfer, and process improvement in companies such as Hybritech, Quidel, Nanogen, and Alere.